CG
VRTX icon

Clinton Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Clinton Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,576
Closed -$257K – 480
2018
Q1 		$257K Sell
1,576
-36,964
-96% -$6.04M 0.03% 319
2017
Q4 		$5.78M Buy
38,540
+34,995
+987% +$5.18M 0.51% 58
2017
Q3 		$539K Buy
+3,545
New +$534K 0.06% 282
2017
Q2 		– Sell
-11,000
Closed -$1.2M – 887
2017
Q1 		$1.2M Buy
+11,000
New +$968K 0.07% 385
2016
Q4 		– Sell
-6,461
Closed -$563K – 1028
2016
Q3 		$563K Buy
+6,461
New +$611K 0.03% 645

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Clinton Group's VRTX Position: Q2 2018 in Review

Clinton Group sold out of Vertex Pharmaceuticals (VRTX) in Q2 2018, closing a stake of 1,576 shares — an estimated $257K sold.

Clinton Group first reported a position in VRTX in Q3 2016 and held it in 5 quarters. The position peaked at $5.78M in Q4 2017. 690 funds tracked by Wall St. Rank hold VRTX as of Q2 2018.

  • Clinton Group reported no remaining Vertex Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Clinton Group sold 1,576 Vertex Pharmaceuticals shares in Q2 2018, an estimated $257K.
  • Clinton Group first reported a position in Vertex Pharmaceuticals in Q3 2016 and held it in 5 quarters.
  • Clinton Group's Vertex Pharmaceuticals position peaked at $5.78M in Q4 2017.
  • 690 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2018.

Based on Clinton Group's 13F filing for Q2 2018, filed 6 Jul 2018.